Evolving concepts in the diagnosis, prognosis, and treatment of pheochromocytoma;Progrès récents dans le diagnostic, l'évaluation pronostique et le traitement des phéochromocytomes

Revue de Medecine Interne

Volumn 21, Issue 12, 2000, Pages 1075-1085

  Plouin, P F ^a   Gimenez Roqueplo, A P ^a   La Batide Alanore, A ^a   Salenave, S ^a   Duclos, J M ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b SAINT JOSEPH HOSPITAL   (France)

Author keywords

Catecholamines; Hereditary disease; Metanephrine; Neoplasm, malignant; Pheochromocytoma; Recurrence

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; METADRENALIN; METIROSINE; PHENOXYBENZAMINE; SOMATOSTATIN DERIVATIVE;

ARTIFICIAL EMBOLISM; CATECHOLAMINE URINE LEVEL; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HUMAN; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; RECURRENT DISEASE; REVIEW; SCINTIGRAPHY;

EID: 0034508136     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)00268-X     Document Type: Short Survey

References (55)

1. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma
2. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation
3. Dépistage du phéochromocytome: Chez quels hypertendus? Étude sémiologique chez 2 585 hypertendus dont 11 ayant un phéochromocytome
4. Selective down-regulation of adrenergic receptor subtypes in tissues from rats with pheochromocytoma
5. The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma
6. Prevalence of clinically unsuspected pheochromocytoma: Review of a 50-year autopsy series
7. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981
8. Hormonal evaluation of the patient with an incidentally discovered adrenal mass
9. Phaeochromocytoma still surprises
10. The pheochromocytoma: A benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?
11. Patients opérés d'un phéochromocytome: Surveillance biologique indéfinie
12. Crises solaires et hypertension paroxystique en rapport avec une tumeur surrénale
13. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
14. Recommandations et références médicales de l'ANAES. Diagnostic et traitement de l'hypertension artérielle essentielle de l'adulte de 20 à 80 ans
15. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease
16. Genetic basis of endocrine disease: Multiple endocrine neoplasia type 2
17. Identification of the von Hippel-Lindau disease tumor suppressor gene
18. Loss of NF1 alleles in phaeochromocytamas from patients with type 1 neurofibromatosis
19. Biochemical tests for the diagnosis of pheochromocytoma: Urinary versus plasma determinations
20. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2
21. Phoechromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy
22. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy
23. Comparison of radiolabeled octreotide and meta-iodobenzyl guanidine (MIBG) scintigraphy in malignant pheochromocytoma
24. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET
25. Pheochromocytoma in multiple endocrine neoplasia type 2: European study
26. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease
27. Lisch nodules in neurofibromatosis type 1
28. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease
29. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas
30. Comment différentier un phéochromocytome sporadique d'un phéochromocytome héréditaire?
31. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype
32. Routine bilateral adrenalectomy is not warranted in childhood familial pheochromocytoma
33. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma
34. Malignant pheochromocytoma: Clinical, biochemical and scintigraphic characterization
35. Pheochromocytomas: Can malignant potential be predicted?
36. A reevaluation of dopamine excretion in pheochromocytoma
37. The pathophysiological basis of current pheochromocytoma management
38. Plasma renin activity in pheochromocytoma: Effects of betablockade and converting enzyme inhibition
39. Facteurs associés à la morbimortalité périopératoire chez les patients ayant un phéochromocytome bénin, récidivant ou malin
40. Use of m-[131I]Iodobenzylguanidine in the treatment of malignant pheochromocytoma
41. Therapeutic embolization of pheochromocytoma
42. Percutaneous injection of an alcoholic embolizing emulsion as an alternative preoperative embolization for spine tumor
43. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine
44. Alpha-Methyl-p-tyrosine: A review of its pharmacology and clinical use
45. The RET protooncogene in sporadic pheochromocytomas: Frequent MEN2-like mutations and new molecular defects
46. High levels of tyrosine phosphorylated proto-Ret in sporadic pheochromocytomas
47. Von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells
48. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma
49. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal and malignant pheochromocytomas
50. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
51. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors
52. Short term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with pheochromocytoma: A placebo-controlled trial
53. Beneficial effects of octreotide in a patient with a metastatic paraganglioma
54. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant pheochromocytoma
55. Phéochromocytomes malins: Histoire naturelle et traitement